Table 1 Clinicopathological Featurse of Cohort (N = 93)
Gender | N (%) |
|---|---|
Female | 33 (35) |
Male | 60 (65) |
Tumor Grade | |
Well or moderatetly differentiated | 40 (43) |
Moderate to poor | 25 (27) |
Poor | 28 (30) |
Stage at Diagnosis* | |
pT1 | 1 (1) |
pT2 | 2 (2) |
pT3 | 90 (97) |
Tumor Location | |
Head | 76 (82) |
Body | 8 (8) |
Tail | 9 (10) |
Lymphovascular Invasion | |
Present | 78 (84) |
Absent | 15 (16) |
Perineural Invasion | |
Present | 88 (95) |
Absent | 5 (5) |
Lymph Node Status* | |
No lymph nodes (N0) | 22 (24) |
N1 | 35 (38) |
N2 | 36 (38) |
Margin status | |
Positive | 23 (25) |
Negative | 70 (75) |
History of neoadjuvant therapy | |
Yes | 6 (6) |
No | 87 (94) |
History of adjuvant therapy | |
Yes | 77 (88) |
No | 11 (12) |
Cancer Stem Cell Markers | |
CD44+/ESA+ | 16 (17) |
CD44+/ESA−. | 19 (20) |
CD44−/ESA+ | 36 (39) |
CD44−/ESA− | 22 (24) |